Iterum Therapeutics Commences Rights Offering DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to...
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections Proposed Date for Advisory Committee meeting is September 9, 2024 DUBLIN, Ireland and CHICAGO, June 21, 2024...
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 – Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – –...
Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD) VGA039 clinical data supports favorable safety profile in healthy volunteers and convenient subcutaneous dosing regimen Oral presentation...
Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) ELA026 demonstrated a high overall response rate (ORR) across a range of sHLH patients and a favorable...
Recent Comments